Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Investor Day (November 2026)
94 slides from Telix Pharmaceuticals's investor day presentation, Nov 4, 2026
Slide 1: Capital Markets Day
rsonal use only Capital Markets Day November 4, 2026 Melbourne, Australia ASX: TLX | NASDAQ: TLX Radiopharmaceutical manufacturing suite at TMS North Melbourne.
Slide 2: Forward looking statement
Forward looking statement This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on
Slide 3: Telix management
Telix management rsonal use only Dr. Christian Behrenbruch Mr. Darren Smith Dr. David N. Cade, MD Managing Director and Group CEO Group Chief Financial Officer Group Chief Medical Officer 3
Slide 4: Key Opinion Leaders
Key Opinion Leaders rsonal use only Prof. Munir Ghesani Dr. Philip Dundee Prof. Louise Emmett Prof. Andrew Scott Nuclear Medicine Physician, Urological Surgeon, Director Director of Theranostics and Professor of Medicine, University of Professor of Radiology Icahn Robotic Surgery Fellowship Nuclear
Slide 5: Strategy & overview
rsonal use only Strategy & overview Dr. Christian Behrenbruch Managing Director and Group CEO
Slide 6: Telix at a glance
Telix at a glance A diversified, vertically integrated radiopharma company rsonal use only Integrated theranostic approach: See It. Treat It. Precision Medicine Specialist commercial Vertically integrated High-value R&D platform for new portfolio organization manufacturing and therapeutics pipeline
Slide 7: Radiopharmaceuticals: a rapidly expanding market
Radiopharmaceuticals: a rapidly expanding market Global nuclear medicine market growth rsonal use only CAGR (10yr): 41 Therapeutics 26% Diagnostics (incl. PET and SPECT tracers) 2024–2034, USD billions 27 CAGR (10yr): Therapeutics Therapeutics: 26% Diagnostics: 5% 11 ~US$3B ~US$27B 2024 2034 2024 20
Slide 8: Three growth engines creating long-term value
Three growth engines creating long-term value Commercial expansion, novel therapies and integrated supply underpin our growth strategy rsonal use only Scaled commercial business Extend market-leading precision medicine 1 commercial position through product innovation, diversification and global expa
Slide 9: Scaled commercial business
1 Scaled commercial business Three FDA approved precision medicine products fuel our commercial engine rsonal use only F D A AP P R O V E D F D A AP P R O V E D F D A AP P R O V E D • Clinical differentiation, proven • First FDA-approved FET-PET track record, year over year imaging drug for glioma4
Slide 10: Expanding addressable market for our commercial business
1 Scaled commercial business Expanding addressable market for our commercial business and near-term commercial products Commercial Products Near-Commercial rsonal use only Illuccix/Gozellix Pixclara Zircaix BiPASS ITM-111 Product Diagnostic Diagnostic Diagnostic Diagnostic Therapeutic Prostate cance
Slide 11: Late-stage pipeline
2 Late-stage pipeline Late-stage therapeutic pipeline transformational to Telix’s growth rsonal use only Late-stage therapeutics U.S. TAM Status Upcoming milestones TLX591-Tx ~$5.6B Phase 3 Interim futility analysis Prostate cancer (mAPMR) ~22,460 Patients TLX597-Tx ~$4.2B Phase 2 Optimal-PSMA data
Slide 12: Vertically integrated manufacturing drives scale and value
3 Best-in-class manufacturing Vertically integrated manufacturing drives scale and value Supply-chain control matters in a sector defined by time-critical delivery, specialist infrastructure, complex regulation and limited suppliers rsonal use only Supply security Speed Economics Less reliance on th
Slide 13: Specialized radiopharma supply chain
3 Best-in-class manufacturing Specialized radiopharma supply chain Building in-house capabilities across critical stages of the value chain rsonal use only Radioisotope supply Irradiation and Isotopes purification Targeting molecules Radiolabelled Unit dose Last-mile drug product delivery Antibody o
Slide 14: In-house radioisotope production capabilities
3 Best-in-class manufacturing In-house radioisotope production capabilities Supports current commercial and late-stage portfolio, plus next generation therapeutics rsonal use only ARTMS – QIS® Technology ITM1 – Global leader in Lu-177 Control over next generation alphas • Radiometal production techn
Slide 15: Global manufacturing and supply chain footprint
Scaled globally, positioned for long-term value Global manufacturing and supply chain footprint rsonal use only Seneffe, Belgium Yokohama, Japan Melbourne, Australia Telix Manufacturing Solutions site Strategic partner 15
Slide 16: Transaction reinforces Telix's growth strategy
Telix & ITM Transaction reinforces Telix’s growth strategy The combination of ITM + Telix enhances our ability to compete rsonal use only Vertically R&D platform High value Precision Specialist for new integrated manufacturing / therapeutics Medicine commercial molecular supply chain pipeline portfo
Slide 17: Telix + ITM positioned to service growing demand
TELIX & ITM Telix + ITM positioned to service growing commercial and clinical demand rsonal use only Radioisotope markets forecast to compound at ~30% p.a. through 20351 INDUSTRY ASSETS IN DEVELOPMENT² 177Lu total market (US$B)1 225Ac total market (US$B)1 US$B Growth to $2.1B risk adjusted by 2035 2
Slide 18: Building a radiopharmaceutical powerhouse
TELIX & ITM Building a radiopharmaceutical powerhouse Positioned for leadership in a fast-growing segment of oncology rsonal use only Why invest now? Specialty Big pharma Capability radiopharma Telix + ITM Secure supply and protect launches Consolidated Consolidated • Ensures Telix has the critical
Slide 19: Creating a fully integrated global radiopharma leader
Telix & ITM Creating a fully integrated global radiopharma leader Strong foundation and geographic footprint to support global therapeutic launches rsonal use only 3x manufacturing Global HQ & 2x sites & 2x manufacturing cyclotrons in BE sites in DE JV TMS Sacramento TMS Yokohama US HQ Cyclotron fac
Slide 20: Pipeline
rsonal use only Pipeline Dr. David N. Cade Group Chief Medical Officer
Slide 21: Late-stage and next generation therapeutic assets
Late-stage and “next generation” therapeutic assets rsonal use only Pixlumi, Zircaix brand names subject to regulatory approval. PSMA: Prostate-specific membrane antigen. PDGFRα: Platelet-derived growth factor receptor alpha. CAIX: Carbonic anhydrase IX. mAb: Monoclonal antibody. LAT1: L-Type amino
Slide 22: Transformative portfolio expansion across early and late-stage assets
Transformative portfolio expansion across early and late-stage assets rsonal use only 1 2 • Co-development and co-commercialization • Adds a complementary therapeutic franchise with agreement to develop candidates focused on alpha multiple pathways for growth therapies • ITM-11 Phase 3 expansion pro
Slide 23: Prostate cancer: 68Ga PSMA-11 in practice
rsonal use only Prostate cancer 68Ga PSMA-11 in practice Dr. Munir Ghesani Chief Medical Officer United Theranostics
Slide 24: 68Ga PSMA-11 has set a high bar in staging and BCR
68Ga PSMA-11 has set a high bar in staging and BCR High-risk, pre-treatment staging1 Biochemical recurrence (Illuccix China study, n = 140)2 rsonal use only (proPSMA randomized trial, n = 295 with follow up) Patient level PPV 94.8% (95% CI: 85.9%, 98.2%) 68Ga PSMA-11 Metric CT + bone scan Baseline P
Slide 25: 68Ga has a lower propensity for indeterminate bone lesions
68Ga has a lower propensity for indeterminate bone lesions (IBLs)1,2 rsonal use only Free 68Ga, in contrast to 18F, Gallium-68 Fluroine-18 does not have an affinity to Free 68Ga is taken up and Free 18F has a naturally high bone metabolized through the liver and affinity to bone. does not have an af
Slide 26: Case study: diagnostic accuracy of 68Ga PSMA-11
Case study: diagnostic accuracy of 68Ga PSMA-11 CT PET PET/CT Fused rsonal use only F-18 PSMA PET Scan PSA 3.4 • Patient on active surveillance • No active treatment IBL detected No rib lesion 68Ga PSMA-11 PET Scan 6 months later Resolution without interval treatment confirms lesion benignity Patien
Slide 27: Case Study
Case Study 68-year-old male; Gleason 9 (4+5) prostate cancer; PSA is 112; Referred for 177Lu-PSMA Therapy (Pluvicto) rsonal use only 18F-PSMA PET Scan 68Ga PSMA-11 PET Scan Multiple lesions accurately identified on 68Ga PSMA-11 PET Scan, but not on 18F-PSMA PET Scan Patient representative case study
Slide 28: Enhancing lesion detection through delayed 68Ga PSMA-11 PET imaging
Beyond standard imaging, enhancing lesion detection through delayed 68Ga PSMA-11 PET imaging rsonal use only 50–100 mins 68 mins >120 mins Labelled acquisition window Physical half-life of ⁶⁸Ga Permitted for indeterminate findings U.S. prescribing information for Approximately one quarter of Joint E
Slide 29: Study design evaluating delayed acquisition with 68Ga PSMA-11
Study design evaluating delayed acquisition with 68Ga PSMA-11 rsonal use only Design Prospective pilot EARLY scan DELAYED scan ~60 mins 150 mins Enrolled 3 patients, prostate cancer Liver analysis 3 cases, fractional reconstructions extended list-mode, standard acquisition fractionally reconstructed
Slide 30: Higher lesion-to-background contrast observed with delayed imaging
Higher lesion-to-background contrast observed with delayed imaging Case study 1 using 68Ga PSMA-11 rsonal use only Early · 60 mins Delayed · 150 mins Patient representative case study for educational purposes only. Individual responses may differ. Does not constitute medical advice or solicitation.
Slide 31: Higher lesion-to-background contrast observed with delayed imaging
Higher lesion-to-background contrast observed with delayed imaging Case 2 using 68Ga PSMA-11 rsonal use only Paratracheal lymph nodes Early · 60 mins Delayed · 150 mins CT correlate · bilateral paratracheal Patient representative case study for educational purposes only. Individual responses nodes m
Slide 32: Delayed imaging preserves lesion uptake, modest increase in SUV peak
Delayed imaging with 68Ga PSMA-11 preserves lesion uptake, with a modest increase in SUV peak rsonal use only 10/ 13 lesions with higher delayed SUVpeak +8% median paired change · range −10.7% to +25.3% 1 h vs 50% delayed reconstruction · mean SUVpeak 5.60 vs 6.24 Source: Study results provided by D
Slide 33: Can delayed imaging with 64-Cu-DOTATATE improve lesion clarity?
Can delayed imaging with 64-Cu-DOTATATE improve lesion clarity adjacent to physiological uptake? rsonal use only PREVAILING ASSUMPTION PRIMARY HYPOTHESIS “Delayed imaging is clearer because background Early imaging yields superior overall lesion clarity tracer washes out.” and a more uniform hepatic
Slide 34: Study design evaluating delayed acquisition with 64-Cu-dotatate
Study design evaluating delayed acquisition with 64-Cu-dotatate A paired, within-patient design with blinded two-alternative forced choice rsonal use only Design Retrospective, paired EARLY DELAYED ~1 h ~24 h Cohort 20 patients, SSTR-positive NET Readers 3 board-certified NM physicians post-injectio
Slide 35: 24-hour delayed imaging shows reduced image uniformity
24-hour delayed imaging shows reduced image uniformity Case 1 using 64-Cu-dotatate rsonal use only MIP · 1 h MIP · 24 h Axial · 1 h Axial · 24 h Patient representative case study for educational purposes only. Individual responses may differ. Does not constitute medical advice or solicitation. Consu
Slide 36: A hepatic lesion conspicuous at 1h was not visible at 24h
A hepatic lesion conspicuous at 1h was not visible at 24h Case 2 using 64-Cu-dotatate rsonal use only MIP · 1 h MIP · 24 h Axial PET · 1 h Axial PET · 24 h CT correlate Patient representative case study for educational purposes only. Individual responses may differ. Does not constitute medical advic
Slide 37: A retroperitoneal lymph node became conspicuous at 24 hours
A retroperitoneal lymph node absent at 1 hour became conspicuous at 24 hours Case 3 using 64-Cu-dotatate rsonal use only Axial PET · 1 h · no focal Axial PET · 24 h · left para-aortic CT correlate · retroperitoneal node, retroperitoneal uptake focus distinct from ureter Patient representative case s
Slide 38: 64Cu-dotatate results
⁶⁴Cu-dotatate results Combined Variable lesionreview detectionofand both time points heterogeneity identified between lesions 1h and 24h with Cuthat imaging neither examination showed alone rsonal use only EARLY ALONE DELAYED ALONE COMBINED REVIEW 104 lesions 82 lesions 115 lesions · +11 over early
Slide 39: PSMA-PET transformed staging and BCR detection
Current state: PSMA-PET transformed staging and BCR detection Initial biopsy protocol has remained unchanged since the addition of MRI rsonal use only Current indications PSMA-PET scans Current TAM: Future indications (in thousands) ~670,000 scans/year Total addressable market BCR 460 Response Initi
Slide 40: Future state: revolutionizes biopsy decision-making
Future state: revolutionizes biopsy decision-making Potential to double the size of the existing PSMA market rsonal use only 1M+1 Current indications Future indications Total addressable market 821,000 Biopsies reduced scans/ year Move imaging utilization to the pre-biopsy stage BCR Response to Moni
Slide 41: Prostate cancer diagnosis
rsonal use only Prostate cancer diagnosis Dr. Philip Dundee Urological surgeon
Slide 42: Current diagnostic pathway relies on invasive biopsies
Current diagnostic pathway for prostate cancer relies on invasive biopsies Template biopsy rsonal use only • Template biopsies require 15-20 samples obtained through an invasive procedure under anesthesia1 • Sampling limitations may miss disease or fail to characterize tumor burden. Biopsies are bli
Slide 43: A significant unmet need remains in the diagnostic pathway
A significant unmet need remains in the diagnostic pathway Biopsies carry real risks4 Areas of biopsy6 rsonal use only Men with elevated PSA values will • Hematuria, rectal bleeding, often be recommended for MRI1, hematospermia Base (top) followed by biopsy • Inconsistent practice around • MRI is no
Slide 44: Key insights from PRIMARY and PRIMARY2
Key insights from PRIMARY and PRIMARY2 Investigator Initiated Studies (IITs) rsonal use only PRIMARY (n = 291)1 Ga-PSMA-PET +mpMRI mpMRI PRIMARY study established Sensitivity 97% 83% proof of concept that Ga- Specificity 40% 53% PSMA-11 PET + mpMRI Negative predictive value 91% 72% improves the dete
Slide 45: Phase 3 BiPASS study for detection of prostate cancer
® Phase 3 study for detection of prostate cancer Biopsy of the Prostate Avoidance Stratification Study (BiPASS) rsonal use only Primary Objective: Registrational study Detection of clinically significant prostate cancer using mpMRI + 68Ga-PSMA-11 PET1 68Ga-PSMA-11 Template biopsy 6- month follow-up
Slide 46: A more precise diagnostic pathway with 68Ga PSMA-11
A more precise diagnostic pathway with 68Ga PSMA-11, enabling targeted use of biopsy Risk rsonal use only stratification Image-guided biopsy Symptoms or PSMA-PET Potential high risk Staging and surgical elevated PSA + mpMRI1 (PI-RADS2 5) planning 68Ga PSMA-11 at diagnosis aims to: • Improve predicti
Slide 47: The future of prostate cancer detection
The future of prostate cancer detection rsonal use only • 72 year old male was negative for Current state suspicious findings 3 MRI acquisitions (PI-RADS <3) • PSMA PET detected a focal uptake in the right anterior apex of the prostate1 Future state 1 PSMA PET scan Patient representative scans – ind
Slide 48: Brain cancer overview
rsonal use only Brain cancer overview (select programs) Prof. Andrew Scott Head of Tumour Targeting Laboratory Olivia Newton- John Cancer Research Institute
Slide 49: First FDA approved imaging agent for gliomas
First FDA approved imaging agent for gliomas (U.S.) rsonal use only • Pixlumi ®1 MAA accepted in Europe • Included in National Comprehensive Cancer Network (NCCN®) guidelines • Inclusion in International guidelines: EANM/EANO/RANO/SNMMI • Expanding into new indication: brain metastases2 • Addresses
Slide 50: Clinician impact
Clinician impact rsonal use only ~70% ~80% of physicians surveyed indicated of referrers rely on NCCN they are ready to prescribe guidelines when ordering imaging Pixclara upon FDA approval for glioma Key insights Majority of referrers rank high >90% differential uptake in glioma and high image qual
Slide 51: A novel mechanism of action overcoming the blood brain barrier
A novel mechanism of action overcoming the blood brain barrier Targeted radiation that provides imaging and therapeutic potential rsonal use only Pixclara TLX101-Tx (131I) • Large amino acid transporters, LAT1 and LAT2 are C TLX102-Tx (211At) highly expressed in gliomas1,2 compared to normal S-S tis
Slide 52: Existing imaging modalities have meaningful limitations
Existing imaging modalities have meaningful limitations Our amino acid PET tracer, TLX101-Px represents an innovative advancement in imaging rsonal use only A side-by-side comparison of sequential T1-weighted post contrast MRI and 18F-FET of the same patient Limitations of CE MRI MRI, the current So
Slide 53: TLX101-Px with MRI: sensitivity 93%, specificity 94%
Combining TLX101-Px with MRI has demonstrated sensitivity of 93% and specificity of 94% for detection of gliomas rsonal use only Comparison of FET PET with standard MRI for the detection of tumor tissue Imaging findings were evaluated histologically 1 Only the biopsy of the FET hot spot yielded TPF
Slide 54: TLX101-Px differentiates treatment changes from disease progression
TLX101-Px in combination with MRI differentiates between treatment related changes and disease progression rsonal use only Patient representative scans – individual results may vary. A 35-year-old patient with initial diagnosis of a diffuse astrocytoma (WHO grade II). Follow-up MRI 86 months after i
Slide 55: Standard of care unchanged for two decades
Standard of care has remained unchanged for the past two decades despite rapid innovation in oncology Pixclara approval FDA Approvals rsonal use only Bevacizumab for TMZ for recurrent recurrent GBM anaplastic astrocytoma Lomustine TMZ for newly Tumor treating Vorasidenib for Gliadel Carmustine diagn
Slide 56: Disease overview: Glioblastoma (GBM)
Disease overview: Glioblastoma (GBM) Burden of GBM is increasing, however survival rates have not improved in 20+ years1 rsonal use only ~25k new brain and CNS Annual incidence (US)1 Average survival (U.S.)1 tumor cases/yr with ~18k 4 60 deaths/yr (U.S.)1 GBM is the most common and Relative Survival
Slide 57: Prior TLX101-Tx studies: favorable safety profile
Prior TLX101-Tx studies have demonstrated favorable safety profile and encouraging efficacy in malignant gliomas rsonal use only Demonstrated safety and Demonstrated early tolerability profile in combination Ongoing trials efficacy results trials with EBRT and TMZ • IPAX-1 (Phase 1), IPAX Linz1 • Me
Slide 58: A global Phase 3 study for TLX101-Tx
TM , A global Phase 3 study for TLX101-Tx Part 1: Dose optimization Part 2: Randomized treatment expansion rsonal use only TLX101-Tx + Primary endpoints (Part 1) TLX101-Tx Eligible TLX101-Tx Lomustine Data review (4 GBq) + Patients (4 GBq) + • Max tolerated dose, MTD and Lomustine Lomustine recommen
Slide 59: TLX101-Tx favorable safety profile, stable disease observed
TLX101-Tx, has demonstrated a favorable safety profile, with stable disease observed Demonstrated favorable safety and tolerability in compassionate use program1 rsonal use only - Grade 3 adverse events, cerebral edema (1), common for this condition, judged not likely due to TLX101-Tx - No Grade 4 a
Slide 60: IPAX-2 Phase 1 study for TLX101-Tx
IPAX-2, Phase 1 study for TLX101-Tx (newly diagnosed GBM) Met Primary endpoint: Max Tolerated Dose (MTD) of 5GBq x 2cycles + SoC achieved rsonal use only Dose escalation Primary endpoints • Safety and tolerability • Max tolerated dose and TLX101-Tx TLX101-Tx TLX101-Tx recommended dose (3 GBq) x 2 cy
Slide 61: Renal cancer (select programs)
rsonal use only Renal cancer (select programs) Dr. David N. Cade Group Chief Medical Officer
Slide 62: Disease overview: Kidney cancer
Disease overview: Kidney cancer Age-standardized rate per 100,000 (2022)4 rsonal use only 14th most commonly diagnosed cancer worldwide1 Age-standardized incidence & mortality highest in North America & Europe1 Twice as common in men vs women1 90% of kidney cancer is RCC, of which ~85% is ccRCC2,3 c
Slide 63: Novel target in ccRCC - CAIX
Novel target in ccRCC - CAIX rsonal use only Transmembrane glycoprotein involved in oxygen-sensing pathways and regulator for pH1,2 Induced by hypoxia or by mutation of the Von Hippel-Lindau tumor suppressor gene1-4 Expressed in >95% of ccRCC5-7 Negligible expression in normal kidney tissue7 Adapted
Slide 64: Monoclonal antibody-based theranostics
Monoclonal antibody-based theranostics TLX250-Tx for treatment of ccRCC and TLX250-Px for imaging Payload: 177Lu (therapy) rsonal use only Girentuximab Payload: 89Zr (imaging) • IgG1 kappa light chain chimeric • Positron emitter • Medium-energy β-emitter monoclonal antibody • Half-life 3.3 days • Ha
Slide 65: TLX250-Px: ZIRCON imaging data validates target in ccRCC
TLX250-Px: ZIRCON imaging data validates target in ccRCC Phase 3 imaging trial and real-world evidence have important insights for therapy program ZIRCON study results summary rsonal use only Primary endpoints: Sensitivity: 86% | Specificity: 87% (n=284) ≤4 cm (n=145) • Sensitivity: 85% Sensitivity
Slide 66: TLX250-Tx: LUTEON and LUTEON-ATLAS trial design
TLX250-Tx: LUTEON (Ph3) and LUTEON-ATLAS (Ph2a) trial design U.S. sites enrolling patients / EU under review US/EU: LUTEON-ATLAS (Ph2a) rsonal use only AUS: LUTEON (Ph3) AUS sites enrolling patients1 Safety Lead-in* Part 1: Dose Optimization (Phase 2a) Part 2 (Phase 3) Population: N=3 N=TBD • Advanc
Slide 67: TLX591-Tx
rsonal use only TLX591-Tx Dr. David N. Cade Group Chief Medical Officer, CMO
Slide 68: Disease progression shifts clinical priorities
Disease progression shifts clinical priorities Distinct prostate cancer disease states bear implications for patient management rsonal use only Androgen pathway modulator sensitive Androgen pathway modulator resistant Prognosis and • Survival commonly extends beyond 4-5 • Approximately 2-3 years fro
Slide 69: Addressing patient needs across the care continuum
Addressing patient needs across the care continuum TLX597-Tx and TLX591-Tx profiles are adapted to each disease state TLX597-Tx: Next gen small molecule1 TLX591-Tx: First-in-class rADC2 rsonal use only • Renal excretion BUT with 1/3rd radiation • Liver excretion (radio-tolerant organ) Excretion orga
Slide 70: TLX591-Tx is a novel therapy candidate for prostate cancer
TLX591-Tx is a novel therapy candidate for prostate cancer Radio antibody-drug conjugate (rADC) Mechanism of Action rsonal use only approach addresses key unmet needs1-4 1. Patient friendly 2-dose / 2-week regimen: Supports compliance to treatment and ease of integration with standard of care (SOC)
Slide 71: Phase 3 ProstACT study for TLX591-Tx
® Phase 3 study for TLX591-Tx Part 1 completed, with FDA alignment to advance to Part 2 in U.S.1 rsonal use only Part 1: Safety and dosimetry: Part 2: Randomized treatment expansion completed TLX591-Tx + Eligible TLX591-Tx (76mCi) x 2 cycles + abiraterone/ Primary endpoints (Part 1) Patients abirate
Slide 72: Patient case: TLX591-Tx (2 doses) + docetaxel
Patient case: TLX591-Tx (2 doses) + docetaxel (6 cycles) 83-year-old patient with bony metastatic lesions1 SPECT TLX591-Tx biodistribution: Single dose Distribution of TLX591-Tx over 15 days2 rsonal use only * Stable disease at day 341 (data cutoff) Post treatment SPECT imaging TLX591-Tx seen in the
Slide 73: Patient case: TLX591-Tx (2 doses) + abiraterone
Patient case: TLX591-Tx (2 doses) + abiraterone 64-year-old patient with metastatic disease in lymph nodes1 SPECT TLX591-Tx biodistribution: Single dose distribution of TLX591-Tx over 15 days rsonal use only * Stable disease for 339 days Post treatment SPECT imaging TLX591-Tx seen in the TLX591-Tx s
Slide 74: Patient case: TLX591-Tx (2 doses) + enzalutamide
Patient case: TLX591-Tx (2 doses) + enzalutamide 62 year-old patient with prior ARPI (darolutamide) and docetaxel1 SPECT TLX591-Tx biodistribution: Single dose distribution of TLX591-Tx over 15 days rsonal use only * Stable disease and on study at 337 days (data cutoff) Administration TLX591-Tx seen
Slide 75: TLX597-Tx
rsonal use only TLX597-Tx Prof. Louise Emmett Director of Theranostics and Nuclear Medicine St Vincent’s Hospital Sydney
Slide 76: TLX597-Tx: Next-Generation PSMA-targeting RLT
TLX597-Tx: Next-Generation PSMA-targeting RLT Targeted mechanism supports enhanced tumor selectivity rsonal use only TLX597-Tx, small molecule candidate with promising early safety and dosimetry data1 Low uptake in salivary glands and kidneys supports improved tolerability and wider therapeutic wind
Slide 77: TLX597-Tx early data suggests favorable dosimetry profile
TLX597-Tx early data suggests favorable dosimetry profile Selective tumor targeting with lower healthy tissue exposure TLX597-Tx SPECT scan, rsonal use only 5 hrs and 120 hrs TLX597-Tx PSMA-6172 PSMA-I&T2 Gy/GBq (n = 12)1 (n = 297) (n = 153) Kidneys 0.28 < 0.58 0.71 Lacrimals 0.35 < 1.58 2.83 Subman
Slide 78: Dose intensification and higher activity to enhance tumor response
Leveraging dose intensification and higher activity to enhance tumor response rsonal use only Dose intensification consists of 2 components PSMA up-regulation can be seen 3 days after the initial dose through higher TTV Dose 1 (Day 1) Dose 2 (Day 3) 1 First 3 doses 2 Higher administered administered
Slide 79: TLX597-Tx, Phase 2 OPTIMAL-PSMA study
TLX597-Tx, Phase 2 OPTIMAL-PSMA study PSA response as Exploring safety and efficacy of dose intensification vs standard treatment well understood surrogate biomarker for rsonal use only small molecules Majority of patients Investigator Initiated Trial (PI: Prof Louise (not for mAbs) Part B received
Slide 80: Patient case: TLX597-Tx treatment post-chemo and ARPI
Patient case: TLX597-Tx treatment post-chemo (2 lines) and ARPI Dose 1 Dose 2 Dose 3 Dose 4 (Day 1) (Day 3) (Day 15) (Week 10) rsonal use only 71-year-old patient with diffuse bone metastases • Normal kidney function • Substantial shrinkage of lesions • 97% PSA response at week 10 Day 1 Day 3 Day 15
Slide 81: Patient case: TLX597-Tx in advanced setting
Patient case: TLX597-Tx in advanced setting Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 (Day 1) (Day 3) (Day 15) (Week 10) (Week 20) rsonal use only Extensive skeletal / bone marrow involvement at baseline • Improvement in hemoglobin • Normal kidney function • 99% PSA response Day 1 Day 3 Day 15 Week 10 Week
Slide 82: TLX597-Tx, Phase 2a OPTIMAL-e study in mAPMN/S
TLX597-Tx, Phase 2 OPTIMAL-e study in mAPMN/S (mHSPC) Adaptive PSMA targeted radioligand therapy rsonal use only 3 doses in 6 weeks 2 doses every 8-weeks 2 doses every 8-weeks Primary endpoint Eligibility Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 Dose 7 • PSA <0.2ng/mL at 6mo. Day 1 Day 8 Day 10 Wee
Slide 83: Case study: OPTIMAL-e
Case study: OPTIMAL-e rsonal use only Patient representative scans - individual results may vary. Source: Emmett, L. Next-generation PSMA therapeutics: The OPTIMAL trial experience, presented at EANM 2026, used with permission. 83
Slide 84: Prostate cancer
rsonal use only Prostate cancer Dr. David N. Cade Group Chief Medical Officer, CMO
Slide 85: Multi-product therapy portfolio in prostate cancer
Multi-product therapy portfolio in prostate cancer Aligned to disease state, patient needs and clinical opportunity rsonal use only Androgen pathway modulator-sensitive Androgen pathway modulator resistant Palliative TLX090-Tx TLX592-Tx TLX597-Tx TLX591-Tx Phase 3 OPTIMAL-e in PSMA+ mAPMR patients p
Slide 86: Financial overview
rsonal use only Financial overview Darren Smith Chief Financial Officer
Slide 87: Financial strength creates strategic choice
Financial strength creates strategic choice A scaled commercial base enables strategic investment for long term value creation rsonal use only 2026 REVENUE GUIDANCE PRECISION MEDICINE NET PROFIT AFTER TAX CASH BALANCE GROSS MARGIN US$950–970M1 65%2 US$38M2 US$252M3 1 2 3 Commercial Strategic optiona
Slide 88: Consistent commercial execution driving sustained growth
1 COM M ERCIAL SCALE Consistent commercial execution driving sustained growth 56% rsonal use only Group revenue ~20% 950 - 9701 US$M 804 56% 517 55% 333 211% 107 2022 2023 2024 2025 2026F Global revenue excluding TMS TMS revenue2 TMS = Telix Manufacturing Solutions. 1. Refers to revenue guidance of
Slide 89: Strategic optionality: disciplined capital allocation
2 Strategic optionality Disciplined capital allocation for sustainable growth rsonal use only Commercial investments R&D investments Investment in the therapeutics and Optimize sales performance, globally precision medicine pipeline Capital allocation Supply resilience Strategic growth opportunities
Slide 90: Disciplined investment
2 Disciplined investment Disciplined R&D investment supported by commercial scale R&D investment focused on late-stage assets Telix R&D investment below peer average rsonal use only R&D spend as % of revenue(1) R&D as % of revenue(1) Average: 35% (2) ✓ Focus capital on opportunities that can expand
Slide 91: ITM combines strong revenue growth with path to positive EBITDA
Telix & ITM ITM Combines Strong Revenue Growth with a Clear Path to Positive EBITDA Strong Revenue Growth Attractive EBITDA Trajectory rsonal use only ITM Revenue ($M)(1) ITM Adjusted EBITDA ($M)(1) ~$50 ~$300 $273 $198 ($12) 2024A 2025A 2026E Manufacturing ITM-11 Future 1H 26A ITM Cost ITM Telix IT
Slide 92: Final remarks
rsonal use only Final remarks Dr. Christian Behrenbruch Managing Director and Group CEO
Slide 93: Transformational period of growth
Transformational period of growth rsonal use only ~US $1B FY 2026E revenue and 3 22 countries 4 Therapeutic candidates in FDA approved imaging Other Income1 Illuccix available late-stage trials2 agents Scaling our commercial Late-stage pipeline Best-in-class business manufacturing & supply Extending
Slide 94: Multiple growth drivers building on a strong 2026 revenue base
Multiple growth drivers building on a strong 2026 revenue base rsonal use only 2 Illustrative revenue bridge $USD 2 3 22+ countries ~$1B1 Key data readouts in 2027: • TLX591-Tx futility analysis • TLX597-Tx OPTIMAL-PSMA • TLX090-Tx (Part A) • BiPASS 2026 Illuccix / Pixclara Zircaix BiPASS Ex-U.S. TM